The initial suggestion of potential benefit for levamisole as adjuvant therapy in colorectal cancer management came from a trial by Verhaegen and colleagues (Verhaegen, 1978; Verhaegen et al., 1982) initiated in 1974. A series of subsequent studies of levamisole in this disease as sole surgical adjuvant have produced less consistent results (Bancewicz et al., 1980; Chlebowski et al., 1982; Sertoli et al., 1987; Arnaud et al., 1989) .
More recently, in trials using combined 5-fluorouracil (5-FU) and levamisole as adjuvant therapy for patients with resected colon cancer more favourable results have been reported. Windle et al. (1989) observed survival benefit of short-course levamisole therapy when combined with 5-FU as compared with 5-FU alone or no adjuvant. In two larger trials, substantial reduction in rate of disease recurrence and patient death on a longer duration levamisole-5-FU combination were reported (Laurie et al., 1989; Moertel et al., 1990) . These results, together with a 'Clinical Alert' from the National Cancer Institute (United States), have led to rapid acceptance of levamisole and 5-FU as standard adjuvant therapy for this disease in the USA, but not universally (National Cancer Institute, 1990; Moertel, 1992) . Against this background, the long-term follow-up of one of the earliest of the levamisole studies, initiated by the Western Cancer Study Group (WCSG) in 1975, is now reported.
Materials and methods

Eligibility
Details of the patient eligibility and study design have been previously reported (Chlebowski et al., 1988 (Chlebowski et al., 1988) .
Overall survival and relapse-free survival represent primary study end points. Cause of death was pursued in all cases and recorded when available. The survival curves were generated using the Kaplan-Meier method with statistical significance between treatments explored using the MantelCox method (Breslow, 1970) . Randomised As expected for a study with long-term follow-up, the relapse-free survival results closely paralleled those based on overall survival. The interval from relapse to death was 547 ± 148 days in the placebo vs 438 ± 143 days (mean + s.e.m.) in the levamisole groups (not significant). Considering all participants, overall survival for patients with Dukes' B lesions exceeded those with Dukes' C lesions with 5 year survival rates of 78% and 46% respectively (P <0.001).
The overall survival of all patients, by randomised treatment group, is depicted in Figure 1 . As seen, survival for placebo-and levamisole-treated patients was similar for the first 5 years. However, mortality after this period has only been associated with levamisole group assignment. For the entire study period, the trend favouring longer survival for resected colorectal cancer patients on placebo over levamisole therapy (68% vs 38% survival) approached statistical significance (P <0.08). As expected for a trial with a relatively modest number of events, 95% confidence intervals for patient group survival were large (86-49% survival for placebo and 51-25% survival for levamisole). For patients surviving 5 years from entry, the chance of subsequent sur- Time on study (days) Figure 1 Overall patient survival by allocated treatment comparing 54 levamisole-treated patients with 24 placebo-treated patients (P < 0.08). (Laurie et al., 1989; Moertel et al., 1990) by its higher levamisole dose, absence of 5-FU, use of placebo and longer duration of patient follow-up. The dose and schedule of levamisole in this WCSG trial was more intensive than that used in the studies involving 5-FU and levamisole from the North Central Oncology Group (Laurie et al., 1989) and InterGroup (Moertel et al., 1990 ) trials (Table IV) . As seen, the cumulative levamisole dose was more than two times greater in the Western Cancer Study Group trial than that used in the trials defining standard therapy regimens in the USA. Although levamisole dose intensity may be related to study outcome seen in the current report, even higher levamisole dosage has been required to demonstrate clinical immune modulation (Stevenson et al., 1991; Janik et al., 1993) , and future clinical trials with levamisole dose intensity greater than the WCSG schedule have been recommended.
An unexpected number of late deaths were identified when patients who had received levamisole were under long-term observation for a study which now has more than 15 years' median follow-up. As the North Central and InterGroup trials in the USA were reported after 7.9 and 3 years' followup respectively, additional follow-up of those studies will be required to determine how levamisole group assignment, with or without 5-FU, influences long-term survival.
No consistent cause of death in the levamisole group could be attributed to toxicity. Agranulocytosis resulted in one levamisole-associated patient death, but no other problems related to myelosuppression have been identified in patients given levamisole. Similarly, although multifocal inflammatory leucoencephalopathy has been reported with adjuvant levamisole regimens which include 5-FU (Hook et al., 1992) , neurological symptoms were not reported by our patients receiving levamisole. Finally, Anthony et al. (1979) reported a substantially increased number of deaths from cardiorespiratory failure in a randomised trial involving perioperative levamisole administration in patients with localised lung cancer, with mortality mostly occurring within 6 weeks of levamisole use. In the current report, mortality in the levamisole group occurred throughout the observation period.
In many respects, the results of this trial are in agreement with other reports. The similar survival for patients receiving placebo and levamisole in the first 5 years as well as the (Laurie et al., 1989; Moertel et al., 1990) . In addition, the infrequency of cancer-related deaths after 5 years and the low risk of long-term deaths from any cause in the placebo arm of this trial are as expected for a non-elderly population of patients treated for localised colorectal cancer. However, the continuing mortality seen in patients given levamisole and followed for an extensive period represents an unanticipated study result. Although other explanations for these observations, including the play of chance in a small sample, must be considered, attention to these results for hypothesis generation is warranted, since clinically effective alternatives to levamisole therapy are available for adjuvant therapy in this disease (O'Connell et al., 1993; Wolmark et al., 1993; Zaniboni et al., 1993) .
The negative results associated with non-specific immune modulation approaches which have been reported in breast cancer trials also suggest that long-term assessment of levamisole adjuvant results in colorectal cancer may be prudent. Using dosage similar to that used in the current study, levamisole shortened response and survival in chemotherapymaintained advanced breast cancer patients (Samal et al., 1984) . As adjuvant, non-specific immune modulation with levamisole or BCG has resulted in either inconsistent (Danish Breast Cancer Group, 1980; Treuniet-Donber et al., 1987) or negative influence (Danish Breast Cancer Group, 1980 ; Early Breast Cancer Trialist Group, 1992) on breast cancer patient outcome when long-term follow-up has been completed. In summary, after over 15 years of follow-up, unexpected late mortality was associated with levamisole group assignment in a randomised, placebo-controlled adjuvant trial in patients with resected colorectal cancer. We conclude: (1) other adjuvant trials in this disease which include levamisole treatment should be explored for long-term survival outcome; and (2) levamisole trials recommending higher dosage without strong preclinical support should proceed with caution. This study was supported by Grants 3ROCA05186-15 and CA08099-12 from the NCI.
